Comparison of targeted fluid therapy and standard methods in heart transplant surgery

Comparison of targeted fluid therapy (GDT) and standard methods for hemodynamic management and fluid therapy in heart transplant surgery

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20190108042294N1

Enrollment

Registered

2020-12-20

Start date

2020-03-25

Completion date

Unknown

Last updated

2021-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hemodynamic management and fluid therapy in transplant surgery.

Interventions

Intervention 1: Intervention group 1: The group that will be monitored with conventional monitoring devices (monitoring patient co Saadat Iran) after anesthesia during heart transplant surgery and whi

Eligibility

Sex/Gender

All

Age

10 Years to No maximum

Inclusion criteria

Inclusion criteria: Patient with dilated cardiomyopathy Ischemic cardiomyopathy Fractional ejection less than 20% NYHA class IV patients who have not responded to medication Congenital heart disease that has not responded to medication or surgery

Exclusion criteria

Exclusion criteria: Patients weigh less than 40 kg Patients weighing more than 120 kg Age less than 10 years

Design outcomes

Primary

Measure	Time frame
Therapeutic dose of inotropic drug in heart transplant surgery. Timepoint: During heart transplant surgery. Method of measurement: During heart transplant surgery, inotropic drug was injected with a therapeutic dose of 0.05-0.2 micrograms per minute per minute, if needed, in groups A and B.;Average time of hospitalization of patients in ICU. Timepoint: After heart transplant surgery, during the patient's stay in the ICU. Method of measurement: During group A and B patients in the ICU through clinical symptoms.;Average time of hospitalization of patients. Timepoint: After transferring patients from the ICU to the cardiac surgery ward. Method of measurement: During hospitalization in cardiac surgery in both groups A and B through the evaluation of clinical symptoms.;Average volume of fluid therapy. Timepoint: During heart transplant surgery. Method of measurement: During heart transplant surgery in group A through patients' clinical symptoms (blood pressure, heart rate) and in group B based on Cardiac Index.;Average time required for ventilation. Timepoint: during hospitalization of patients in the ICU. Method of measurement: During hospitalization in ICU based on respiratory parameters of patients connected to ventilation device in both groups A and B.	—

Measure

Time frame

Therapeutic dose of inotropic drug in heart transplant surgery. Timepoint: During heart transplant surgery. Method of measurement: During heart transplant surgery, inotropic drug was injected with a therapeutic dose of 0.05-0.2 micrograms per minute per minute, if needed, in groups A and B.;Average time of hospitalization of patients in ICU. Timepoint: After heart transplant surgery, during the patient's stay in the ICU. Method of measurement: During group A and B patients in the ICU through clinical symptoms.;Average time of hospitalization of patients. Timepoint: After transferring patients from the ICU to the cardiac surgery ward. Method of measurement: During hospitalization in cardiac surgery in both groups A and B through the evaluation of clinical symptoms.;Average volume of fluid therapy. Timepoint: During heart transplant surgery. Method of measurement: During heart transplant surgery in group A through patients' clinical symptoms (blood pressure, heart rate) and in group B based on Cardiac Index.;Average time required for ventilation. Timepoint: during hospitalization of patients in the ICU. Method of measurement: During hospitalization in ICU based on respiratory parameters of patients connected to ventilation device in both groups A and B.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactRonak Benisi

Tehran University of Medical Sciences

ronak_ben90@yahoo.com0098 21 2122341024

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026